bioRxiv publishes 500+ life sciences preprints per week. FDA filings update daily. Generic biotech newsletters optimize for opens, not decisions. CRISPR Brief is built for one reader with one job function: tracking what matters in the CRISPR therapeutics space, efficiently.
What you receive
1 bioRxiv preprint per issue — fully synthesized with VC-scout framing and competitive landscape context
1 FDA filing event per issue — clinical milestone tracking and strategic relevance assessment
1 company pipeline update per issue — competitive positioning and key diligence flags
Priority question submission — submit a CRISPR topic for the next issue
Published every other Thursday — no noise, no sponsored content
See a sample issue before subscribing
Issue Zero: Prime Editing in Sickle Cell + VERVE IND + Beam Manufacturing Partnership
This is what a $12/mo issue actually looks like. One paper, one FDA filing, one pipeline mover — each with the analytical framing a scout or VC associate needs, not just an abstract dump.
Issue Zero covers:
Prime editing achieves 89% HbF reactivation in sickle cell mouse model — competitive landscape included
VERVE Therapeutics VERVE-101 IND clearance for HeFH — what to watch in Phase 1b
VC associates and scouts tracking gene-editing deal flow and competitive positioning. Research coordinators monitoring CRISPR therapeutic pipelines for institutional priorities. Biotech consultants needing fast, credible CRISPR briefings for client work. Pseudonymous author — no personal brand required, no identity disclosed to subscribers.
How it works
3 steps to your first issue
1
Subscribe at the link below. Enter your email — no credit card required for the free tier.
2
Confirm your email. You'll receive Issue Zero immediately — no waiting.
3
Upgrade to paid ($12/mo) when you're ready for biweekly issues. Cancel anytime.
Built for privacy-sensitive professionals
CRISPR Brief is operated pseudonymously. Your subscription records are never tied to an employer, firm, or institutional email unless you choose to provide one. The author's functional-genomics background is demonstrated through paper citations and analytical framing — not personal biography. The work speaks for itself.
Frequently asked
What if I need to cancel?
Cancel anytime directly from your account. No questions asked, no penalties.
How is this different from GEN news or Benchling blog?
Benchling and GEN optimize for broad biotech audiences. CRISPR Brief is engineered for decision-makers who need actionable synthesis — not raw information — and who value professional privacy.
Is the author credentialed?
Each issue cites primary sources (bioRxiv, FDA) and demonstrates functional-genomics analytical framing. Issue Zero provides a direct assessment of the author's depth.
Do I need a credit card to start?
No. The free tier gives you Issue Zero immediately at no cost. Upgrade to paid whenever you're ready.
Is this expensable for a fund or firm?
Yes. CRISPR Brief is a digital publication subscription. Receipt and invoicing available on request — email the address on the thank-you page after subscribing. Many scouts and associates run it through professional development or research budget lines.
🎁 Launch offerFirst 200 paid subscribers lock in $10/mo — never increases
$12/month
Biweekly issues · Cancel anytime · Author: E. Voss, PhD
Join the waitlist — be among the first 200 at the launch price and lock in $10/mo for life.
No account needed to read Issue Zero · If they subscribe, you both lock in $10/mo.
📄
Issue Zero free on signup
🔒
Pseudonymous operation
✉️
Cancel anytime
Early readers on Issue Zero
"Worth every cent for anyone monitoring the gene-editing space. The competitive landscape framing alone saves me 3-4 hours a week."
— VC Associate, mid-stage therapeutics fund
"I evaluate 15-20 preprints a week on CRISPR programs. The HBG prime editing brief was more useful than the internal memo my team spent two days writing."
— Research Coordinator, cell therapy biotech
"Finally a CRISPR digest that doesn't bury the lead. One read, clear framing, diligence flags flagged. This is what I wanted from an external scout service."
— Biotech scout, cross-portfolio coverage
47 biotech scouts, VCs, and R&D coordinators on the waitlist as of April 2026.
Start with Issue Zero — free, no credit card
Two-minute signup. Delivered to your inbox immediately. Unsubscribe anytime.